

Table. Knowledge of human risks associated with avian influenza, European region, 2006*

	Response, no. (%)		
	True	False	Don't know
Transmission risks			
The avian influenza virus can be transmitted between humans	9,864 (33.8)	16,574 (56.8)	2,732 (9.4)
Humans can catch avian influenza by touching contaminated birds	22,722 (77.9)	4,473 (15.3)	1,975 (6.8)
Food-related risks			
Even when it is contaminated, poultry is not a health risk if it is cooked	17,906 (61.4)	8,536 (29.3)	2,728 (9.4)
The avian influenza virus contained in an egg or present on its shell can be eliminated by prolonged cooking	17,369 (59.5)	6,593 (22.6)	5,208 (17.9)
It is not dangerous to eat the meat of a chicken vaccinated against avian influenza	12,833 (44.0)	9,272 (31.8)	7,065 (24.2)
Other			
The vaccination against seasonal influenza is also effective against avian influenza	4,265 (14.6)	20,847 (71.5)	4,058 (13.9)
If a chicken is contaminated by avian influenza on a farm, all the poultry on that farm must be destroyed immediately	24,492 (84.0)	2,725 (9.3)	1,953 (6.7)

*Source: Eurobarometer 65.2 (http://ec.europa.eu/public_opinion/archives/eb/eb65/eb65_ee_exec.pdf). Information in **boldface** refers to the correct answer.

and human-to-human virus transmission leaves areas for further work.

These results support previous findings that knowledge about avian influenza, especially about prevention and human-to-human transmission, has scope for improvement (4,5). Persons in Europe reported that they have little ability to prevent themselves from getting avian influenza (6). Previous research in the Lao People's Democratic Republic examined how consumers' knowledge of avian influenza risk reduced the likelihood that consumers will substitute poultry for other foods during an avian influenza crisis. This research indicates the importance of informing persons about consumption and transmission-related risks to reduce the likelihood of unnecessary behavioral changes that can cause larger macrolevel market effects (7).

The state of knowledge about avian influenza in Europe during the outbreak in the spring of 2006 leaves room for further public health information campaign efforts, especially those that increase consumers' understanding of consumption-related avian influenza risks. Persons in Europe appear to be aware of culling procedures and the risks of touching infected birds but have a more limited understanding of how avian influenza in their region should influence their consumption patterns.

Elias Mossialos and Caroline Rudisill

Author affiliation: London School of Economics, London, UK

DOI: 10.3201/eid1412.080858

References

1. Sanco DG. Confirmed human cases of avian influenza since 1997 sorted by subtypes [cited 2008 May 27]. Available from http://ec.europa.eu/health/ph_threats/com/Influenza/avian_influenza_human_en.htm
2. Eurobarometer. Avian influenza June 2006 [cited 2008 Mar 15]. Available from http://ec.europa.eu/public_opinion/archives/ebs/ebs_257_en.pdf
3. World Health Organization. H5N1 avian influenza: timeline of major events [cited 2008 May 22]. Available from http://www.who.int/csr/disease/avian_influenza/ai_timeline/en/index.html
4. Abbate R, Di Giuseppe G, Marinelli P, Angelillo IF. Knowledge, attitudes, and practices of avian influenza, poultry workers, Italy. *Emerg Infect Dis*. 2006;12:1762–5.
5. Di Giuseppe G, Abbate R, Albano L, Marinelli P, Angelillo IF. A survey of knowledge, attitudes and practices towards avian influenza in an adult population of Italy. *BMC Infect Dis*. 2008;8:36.
6. De Zwart O, Veldhuijzen IK, Elam G, Aro AR, Abraham T, Bishop GD, et al. Avian influenza risk perception, Europe and Asia. *Emerg Infect Dis*. 2007;13:290–3.
7. Suder G, Inthavong S. New health risks and sociocultural contexts: bird flu impacts on consumers and poultry business in Lao PDR. *Risk Anal*. 2008;28:1–12. DOI: 10.1111/j.1539-6924.2008.00997.x

Address for correspondence: Caroline Rudisill, London School of Economics, LSE Health, Cowdray House, Houghton St, London WC2 2AE, UK; email: a.c.rudisill@lse.ac.uk

Human *Salmonella* Infection Yielding CTX-M β -Lactamase, United States

To the Editor: In the United States most third-generation cephalosporin resistance among salmonellae is due to AmpC plasmid-mediated β -lactamases. Extended-spectrum β -lactamases (ESBLs) have rarely been reported (1). The CTX-M β -lactamases constitute a group of ESBL enzymes that are increasing in prevalence worldwide. Currently, the CTX-M enzymes are classified into 5 different subgroups on the basis of DNA sequence similarities (2). We report on a domestically acquired CTX-M-producing *Salmonella* isolate in the United States.

In 2003, public health laboratories in all US state health departments submitted every 20th non-Typhi *Salmonella* (NTS) isolate from humans

to the Centers for Disease Control and Prevention (CDC) for susceptibility testing by the National Antimicrobial Resistance Monitoring System (NARMS). MICs were determined by broth microdilution and interpreted according to Clinical and Laboratory Standards Institute standards (www.clsi.org), when available. Resistance to cefquinome was defined as ≥ 32 mg/L.

Among the 1,864 human NTS isolates submitted to NARMS in 2003, 105 (5.6%) displayed elevated MICs (≥ 2 mg/L) to ceftriaxone or ceftiofur, third-generation cephalosporins used in human and veterinary medicine, respectively. Genomic DNA was prepared from the 105 isolates, and a PCR with degenerate primers capable of detecting all CTX-M enzymes identified a single positive *S. enterica* ser. Typhimurium (3). The isolate came from a stool sample collected in September 2003 from a white, non-Hispanic, US-born, 3-month-old boy who lived in the state of Georgia. The patient had diarrhea and fever for ≈ 1 week. Because neither the patient nor his family had traveled internationally in the 3 months before specimen collection, the infection appears to have been domestically acquired. The patient did not receive any antimicrobial agents before illness but was treated for 14 days with cefpodoxime. The infant recovered from the illness without complications.

The isolate displayed resistance to β -lactams, aminoglycosides, phenicols, tetracyclines, and folate pathway inhibitors (Table). Two β -lactamases (isoelectric pH [pI] 7.5 and 8.8) were resolved by isoelectric focusing.

Group-specific PCR primers were used to characterize the presumed *bla*_{CTX-M} gene (4). Primers TOH01–2F and TOH01–1R yielded a 351-bp product, confirming a group II *bla*_{CTX-M} gene. To perform sequencing of the entire gene, a ClustalW alignment with representatives from group II was performed to identify primers

Table. MIC values of antimicrobial drugs for the *Salmonella* ser. Typhimurium isolate and its *Escherichia coli* DH10B transformant

Antimicrobial agent	MIC, mg/L		
	<i>S. ser.</i> Typhimurium	<i>E. coli</i> DH10B transformant	<i>E. coli</i> DH10B
Amikacin	1	1	1
Amoxicillin–clavulanic acid	32	16	4
Ampicillin	>32	>32	4
Aztreonam	32	32	0.12
Cefepime	32	32	≤ 0.06
Cefotaxime	>64	>64	≤ 0.06
Cefotaxime–clavulanic acid	0.25	0.12	≤ 0.06
Cefoxitin	2	8	8
Cefquinome	>32	>32	≤ 0.06
Ceftazidime	8	8	0.5
Ceftazidime–clavulanic acid	0.5	0.25	0.12
Ceftiofur	>8	>8	0.5
Ceftriaxone	>64	>64	≤ 0.25
Chloramphenicol	>32	≤ 2	≤ 2
Ciprofloxacin	≤ 0.016	≤ 0.016	≤ 0.16
Gentamicin	4	≤ 0.25	≤ 0.25
Imipenem	0.5	0.25	0.25
Kanamycin	>64	≤ 8	≤ 8
Nalidixic acid	4	1	1
Piperacillin–tazobactam	>64	2	2
Streptomycin	≤ 32	>64	>64
Sulfisoxazole	>256	≤ 16	≤ 16
Tetracycline	>32	≤ 4	≤ 4
Trimethoprim–sulfamethoxazole	>4	≤ 0.12	≤ 0.12

(DNASTAR, Madison, WI, USA). The sequence of the gene was identical to the sequence of the *bla*_{CTX-M-5} gene detected in other isolates of *S. enterica* ser. Typhimurium (GenBank accession nos. U95364 and AF286192) as well as to the *kluA-2* gene of *Kluyvera ascorbata* (GenBank accession no. AJ251722).

The genetic environment of the *bla*_{CTX-M-5} gene was investigated by PCR specific for upstream insertion elements (*ISEcpI*, IS26, and ORF513) and the downstream sequence *sull* (5). Amplification with primer *ISEcpI* and an internal *bla*_{CTX-M-5} primer yielded a PCR product of ≈ 350 bp. Sequencing confirmed presence of the 3' end inverted repeat region of the *ISEcpI*.

Presence of other β -lactamase–encoding genes (*bla*_{TEM}, *bla*_{SHV}, and *bla*_{OXA}) was investigated by PCR (6–8). Amplification with primers OXA-1F and OXA-1R yielded a 595-bp product with a sequence consistent with that of *bla*_{OXA-1} (8).

To determine whether the CTX-M enzyme was plasmid-borne, plasmids were extracted and transformed into electrocompetent *Escherichia coli* DH10B. The transformant exhibited resistance to cefotaxime but not to ceftazidime (Table). In addition, the transformant exhibited resistance to cefquinome and cefepime. The presence of a *bla*_{CTX-M} gene was confirmed by PCR (3,4). The *bla*_{OXA} gene could not be amplified from the *E. coli* transformant (8).

A CTX-M–producing *Salmonella* isolate has been reported only once previously in the United States (9). This was in 1994, when an isolate of *Salmonella* ser. Typhimurium var. Copenhagen with a CTX-M-5 was recovered from a 4-month-old girl adopted from Russia; that infection was not domestically acquired (9). We compared the 1994 isolate and the isolate in this study by pulsed-field gel electrophoresis; the isolates showed distinct patterns.

The *ISEcp1* insertion sequence has been described as a flanking region of several *bla*_{CTX-M} genes and has been implicated in the expression and mobilization of the genes (5). A recent study by Lartigue et al. showed that a CTX-M-2 progenitor in *K. ascorbata* could be mobilized and transferred to a conjugative *E. coli* plasmid by the *ISEcp1B* element; enhanced mobilization was observed in the presence of ceftazidime, cefotaxime, and piperacillin (10).

This *Salmonella* isolate's resistance to cefepime and cefquinome, fourth-generation cephalosporins, is troubling. Cefquinome is not approved for use in the United States but has been used in Europe for treating food animals since 1994. ESBLs, including CTX-M enzymes, are more common in Europe than in the United States (1). Further studies are warranted to clarify the extent to which the use of cefquinome has contributed to high CTX-M prevalence in Europe.

In conclusion, we report a domestically acquired CTX-M-producing *Salmonella* isolate in the United States. Because third-generation cephalosporins are important for treating invasive *Salmonella* infections, continued monitoring of ESBL-producing bacteria is important.

Acknowledgments

We thank the NARMS-participating public health laboratories for submitting isolates, Matt Mikoleit for confirming the *Salmonella* serotype, Anne Whitney for DNA sequencing, and the Georgia Division of Public Health for providing patient interview information.

This work was supported by an inter-agency agreement between CDC and the Food and Drug Administration Center for Veterinary Medicine.

**Maria Sjölund, Jennifer Yam,
Jillian Schwenk, Kevin Joyce,
Felicitia Medalla,
Ezra Barzilay,
and Jean M. Whichard**

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Sjölund, J. Yam, J. Schwenk, K. Joyce, F. Medalla, E. Barzilay, J.M. Whichard); and Atlanta Research and Education Foundation, Atlanta (M. Sjölund, J. Yam, K. Joyce)

DOI: 10.3201/eid1412.080494

References

1. Bush K. Extended-spectrum beta-lactamases in North America, 1987–2006. *Clin Microbiol Infect*. 2008;14(Suppl 1):134–43. DOI: 10.1111/j.1469-0691.2007.01848.x
2. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. *Antimicrob Agents Chemother*. 2004;48:1–14. DOI: 10.1128/AAC.48.1.1-14.2004
3. Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, De Champs C, et al. Effect of D240G substitution in a novel ESBL CTX-M-27. *J Antimicrob Chemother*. 2003;52:29–35. DOI: 10.1093/jac/dkg256
4. Pitout JD, Hossain A, Hanson ND. Phenotypic and molecular detection of CTX-M-beta-lactamases produced by *Escherichia coli* and *Klebsiella* spp. *J Clin Microbiol*. 2004;42:5715–21. DOI: 10.1128/JCM.42.12.5715-5721.2004
5. Eckert C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, et al. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. *Antimicrob Agents Chemother*. 2004;48:1249–55. DOI: 10.1128/AAC.48.4.1249-1255.2004
6. Brinas L, Zarazaga M, Saenz Y, Ruiz-Larrea F, Torres C. Beta-lactamases in ampicillin-resistant *Escherichia coli* isolates from foods, humans, and healthy animals. *Antimicrob Agents Chemother*. 2002;46:3156–63. DOI: 10.1128/AAC.46.10.3156-3163.2002
7. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of *Escherichia coli* during multiple episodes of bacteremia. *Antimicrob Agents Chemother*. 1997;41:647–53.
8. Chen S, Zhao S, White DG, Schroeder CM, Lu R, Yang H, et al. Characterization of multiple-antimicrobial-resistant salmonella serovars isolated from retail meats. *Appl Environ Microbiol*. 2004;70:1–7. DOI: 10.1128/AEM.70.1.1-7.2004
9. Zirnstein G, Swaminathan B, Angulo F, Tenover F, Rasheed JK. Plasmid-mediated CTX-M-5 beta-lactamase conferring resistance to ceftriaxone and cefotaxime in a *Salmonella* serotype Typhimurium var. Copenhagen isolate from an infant adopted from Russia. In: Proceedings of the 2nd International Conference on Emerging Infectious Diseases, Atlanta, Georgia, USA, July 16–19, 2000. Washington: American Society for Microbiology; 2000.
10. Lartigue MF, Poirel L, Aubert D, Nordmann P. In vitro analysis of *ISEcp1B*-mediated mobilization of naturally occurring beta-lactamase gene *bla*_{CTX-M} of *Kluyvera ascorbata*. *Antimicrob Agents Chemother*. 2006;50:1282–6. DOI: 10.1128/AAC.50.4.1282-1286.2006

Address for correspondence: Maria Sjölund, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G29, Atlanta GA 30333, USA; email: fwt4@cdc.gov

***Yersinia pseudotuberculosis* O:1 Traced to Raw Carrots, Finland**

To the Editor: Illness caused by *Yersinia pseudotuberculosis* is mainly characterized by fever and acute abdominal pain due to mesenteric lymphadenitis that mimics appendicitis. Secondary manifestations include erythema nodosum and reactive arthritis (1). Outbreaks have been reported in the Northern Hemisphere, including Canada (2,3), Japan (4), and Russia (5). Several community outbreaks have also been reported in Finland since 1982 (1,6–9). Only in a few of the outbreaks has the vector or source of the infection been identified. Recently, fresh produce, such as iceberg lettuce (7) and carrots (9), has been implicated by epidemiologic investigations as a source of infection, but mechanisms of contamination of fresh produce have remained unknown.

On April 8, 2004, the National Public Health Institute of Finland was informed of several cases of gastroen-